<DOC>
	<DOCNO>NCT01431456</DOCNO>
	<brief_summary>Rationale : After total knee arthroplasty ( TKA ) surgery , patient risk develop venous thromboembolism ( VTE ) deep venous thrombosis ( DVT ) potentially result fatal pulmonary embolism ( PE ) . Two novel agent , dabigatran rivaroxaban , recently gain market authorisation prevention venous thromboembolism knee arthroplasty . However , clinical trial dabigatran and/or rivaroxaban comparator nadroparin . Nadroparin use Dutch department orthopaedic surgery total knee arthroplasty . Also safety new oral agent long term use 42 day available total knee arthroplasty . Our aim compare long term use dabigatran rivaroxaban versus nadroparin safety total knee arthroplasty ( TKA ) clinical explorative pilot study observe incidence major bleed clinical relevant non-major bleeding use standardized model bleed definition . Objective : The primary objective study compare clinical safety long term use oral daily unmonitored thrombin inhibitor dabigatran rivaroxaban versus subcutaneous administer nadroparin observe incidence major bleed clinical relevant non-major bleeding patient knee arthroplasty surgery . The secondary objective study effectivity agent , compliance , hospital stay , re-hospitalisation , outpatient clinic visit intervention follow complication . Additionally , coagulation monitoring , knee flexion range motion , Knee injury Osteoarthritis Outcome Score ( KOOS ) , Knee Society Score ( KSS ) relationship health status surgery parameter evaluate . Study design : The study design non-inferiority randomize open label control pilot study . A total 150 patient include , 50 patient treatment group ( dabigatran , rivaroxaban nadroparin ) . Study population : Patients â‰¥ 18 year weigh 40 kg , participate 'joint care program ' primary elective total knee arthroplasty want provide sign informed consent eligible study . Intervention : Patients receive subcutaneously nadroparin oral rivaroxaban oral dabigatran knee replacement surgery . Main study parameters/endpoints : The primary safety outcome incidence bleed event occur study period 135 day ( include follow-up ) . Major bleed event clinically relevant non-major bleeding event define accord accept guideline .</brief_summary>
	<brief_title>Safety DAbigatran RIvaroxaban Versus NAdroparin Prevention Venous Thromboembolism After Knee Arthroplasty Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<criteria>Patients &gt; 18 year weigh 40 kg schedule primary elective total knee arthroplasty accord 'joint care program ' want provide sign informed consent eligible study . know inherited acquire clinically significant active high risk bleed bleed disorder ; major surgery , trauma , uncontrolled severe arterial hypertension , myocardial infarction within last 3 month ; history acute intracranial disease hemorrhagic stroke ; gastrointestinal urogenital bleeding ulcer disease within last 6 month ; cirrhotic patient moderate hepatic impairment ( aspartate alanine aminotransferase ( AST , ALT ) level higher 2x upper limit normal range ( ULN ) within last month ) ; severe renal insufficiency ( creatinine clearance &lt; 30 mL/min ) ; treatment anticoagulant study drug treatment ; active malignant disease ; pregnancy breastfeeding ; unable give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Prevention</keyword>
	<keyword>venous thromboembolism knee arthroplasty</keyword>
</DOC>